Effects of Beta-blocking Agent Carteolol on Healthy Volunteers and Glaucoma Patients.
- Author:
Man Soo KIM
1
;
Chan Ju LEE
;
Jae Ho KIM
Author Information
1. Deparment of Ophthalmology, Kangnam St. Mary's Hospital, Catholic Medical College, Seoul, Korea.
- Publication Type:Original Article
- MeSH:
Blood Pressure;
Carteolol*;
Glaucoma*;
Glaucoma, Open-Angle;
Healthy Volunteers*;
Heart Rate;
Humans;
Intraocular Pressure;
Ocular Hypertension;
Pupil
- From:Journal of the Korean Ophthalmological Society
1986;27(3):333-340
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The effects of topically applied cartoelol, a beta-adrenergic blocking drug, on intraocular pressure, pupil diameter, pulse rate, and blood pressure and adverse effects were studied in fifteen healthy volunteers and six ocular hypertension, and fifteen chronic open angle glaucoma patients. In control study, the fifteen healthy volunteers were enrolled. Carteolol hydrochloride ophthalmic solution in concentrations of 1%, 2% was instilled, and the IOP, pulse rate, blood pressure, and pupillary diameter were measured before and after 1, 2, 4, 6, 8, and 12 hours. The same method was repeated to evaluate the early effects at six ocular hypertensions and fifteen chronic open angle glaucoma patients. And to evaluate the long term effects, carteolol(one or two percent) was instilled twice daily and IOP, pulse rate, blood pressure, and pupillary diameter were checked before and 1, 2, 4, and 8 weeks after the instillation in ocular hypertension and chronic open angle glaucoma patients. Two concentrations of carteolol were used; 1%, 2%, if their first intraocular pressure were measured above 25 mmHg, the 2% carteolol was used, and if their pressure were measured below 25mmHg, 1% carteolol was used. The results were as follows: 1. The early intraocular pressure reduction effect in healthy volunteers was significant statistically except at 12 hours, and the maximum intraocular reduction was noted at 4 hours (23.3% and 24.3%) respectively. 2. The early intraocular pressure reduction effect in ocular hypertension and POAG-patients was significant statistically except at 1 hour and the maximum intraocular reduction was noted at 4 hours (30.8% and 33.8%), respectively. 3. The long term intraocular pressure reduction effect was significant statistically and the maximum IOP reduction was noted at 2 weeks (29.2% and 31.8%) respectively and 3 patients received the additional therapy. 4. The systemic blood pressure and pulse rate were slightly decreased but not significant statistically and no ocular change was demonstrated by routine ophthalmie examinations following the administration of carteolol solution. On the basis of the results both 1% and 2% carteolol are considered to be optimal to be clinically used in patients with glaucoma.
